Literature DB >> 28838992

The role of constitutive activation of FMS-related tyrosine kinase-3 and NRas/KRas mutational status in infants with KMT2A-rearranged acute lymphoblastic leukemia.

Henning Fedders1, Ameera Alsadeq1, Juliane Schmäh1, Fotini Vogiatzi1, Martin Zimmermann2, Anja Möricke1, Lennart Lenk1, Udo Zur Stadt3, Martin A Horstmann3, Rob Pieters4, Martin Schrappe1, Martin Stanulla2, Gunnar Cario1, Denis M Schewe5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28838992      PMCID： PMC5664404          DOI： 10.3324/haematol.2017.169870

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  14 in total

1.  Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification.

Authors:  Scott A Armstrong; Andrew L Kung; Meghann E Mabon; Lewis B Silverman; Ronald W Stam; Monique L Den Boer; Rob Pieters; John H Kersey; Stephen E Sallan; Jonathan A Fletcher; Todd R Golub; James D Griffin; Stanley J Korsmeyer
Journal:  Cancer Cell       Date:  2003-02       Impact factor: 31.743

2.  Prognostic significance of FLT3 mutational status and expression levels in MLL-AF4+ and MLL-germline acute lymphoblastic leukemia.

Authors:  M C Chillón; M T Gómez-Casares; C E López-Jorge; C Rodriguez-Medina; A Molines; M E Sarasquete; M Alcoceba; J D G-S Miguel; C Bueno; R Montes; F Ramos; J N Rodríguez; P Giraldo; M Ramírez; R García-Delgado; J L Fuster; M González-Díaz; P Menendez
Journal:  Leukemia       Date:  2012-06-18       Impact factor: 11.528

3.  Prognostic significance of high-level FLT3 expression in MLL-rearranged infant acute lymphoblastic leukemia.

Authors:  Ronald W Stam; Pauline Schneider; Paola de Lorenzo; Maria G Valsecchi; Monique L den Boer; Rob Pieters
Journal:  Blood       Date:  2007-10-01       Impact factor: 22.113

4.  Gene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children's Oncology Group study.

Authors:  Huining Kang; Carla S Wilson; Richard C Harvey; I-Ming Chen; Maurice H Murphy; Susan R Atlas; Edward J Bedrick; Meenakshi Devidas; Andrew J Carroll; Blaine W Robinson; Ronald W Stam; Maria G Valsecchi; Rob Pieters; Nyla A Heerema; Joanne M Hilden; Carolyn A Felix; Gregory H Reaman; Bruce Camitta; Naomi Winick; William L Carroll; ZoAnn E Dreyer; Stephen P Hunger; Cheryl L Willman
Journal:  Blood       Date:  2011-12-30       Impact factor: 22.113

5.  Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia.

Authors:  Ronald W Stam; Monique L den Boer; Pauline Schneider; Peter Nollau; Martin Horstmann; H Berna Beverloo; Ella van der Voort; Maria G Valsecchi; Paola de Lorenzo; Stephen E Sallan; Scott A Armstrong; Rob Pieters
Journal:  Blood       Date:  2005-06-14       Impact factor: 22.113

6.  Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.

Authors:  Y Yamamoto; H Kiyoi; Y Nakano; R Suzuki; Y Kodera; S Miyawaki; N Asou; K Kuriyama; F Yagasaki; C Shimazaki; H Akiyama; K Saito; M Nishimura; T Motoji; K Shinagawa; A Takeshita; H Saito; R Ueda; R Ohno; T Naoe
Journal:  Blood       Date:  2001-04-15       Impact factor: 22.113

7.  K-Ras mutations and N-Ras mutations in childhood acute leukemias with or without mixed-lineage leukemia gene rearrangements.

Authors:  Der-Cherng Liang; Lee-Yung Shih; Jen-Fen Fu; Huei-Ying Li; Hsiu-I Wang; Iou-Jih Hung; Chao-Ping Yang; Tang-Her Jaing; Shu-Huey Chen; Hsi-Che Liu
Journal:  Cancer       Date:  2006-02-15       Impact factor: 6.860

8.  FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy.

Authors:  Takeshi Taketani; Tomohiko Taki; Kanji Sugita; Yoshiyuki Furuichi; Eiichi Ishii; Ryoji Hanada; Masahiro Tsuchida; Kenichi Sugita; Kohmei Ida; Yasuhide Hayashi
Journal:  Blood       Date:  2003-09-22       Impact factor: 22.113

9.  Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in infants.

Authors:  Emma M C Driessen; Eddy H J van Roon; Jill A P Spijkers-Hagelstein; Pauline Schneider; Paola de Lorenzo; Maria Grazia Valsecchi; Rob Pieters; Ronald W Stam
Journal:  Haematologica       Date:  2013-02-12       Impact factor: 9.941

Review 10.  The Biology and Targeting of FLT3 in Pediatric Leukemia.

Authors:  Colleen E Annesley; Patrick Brown
Journal:  Front Oncol       Date:  2014-09-23       Impact factor: 6.244
View more
  2 in total

1.  IL7R is associated with CNS infiltration and relapse in pediatric B-cell precursor acute lymphoblastic leukemia.

Authors:  Ameera Alsadeq; Lennart Lenk; Anila Vadakumchery; Antony Cousins; Christian Vokuhl; Ahmad Khadour; Fotini Vogiatzi; Felix Seyfried; Lueder-Hinrich Meyer; Gunnar Cario; Elias Hobeika; Klaus-Michael Debatin; Christina Halsey; Martin Schrappe; Denis M Schewe; Hassan Jumaa
Journal:  Blood       Date:  2018-08-28       Impact factor: 22.113

2.  Clinicopathologic characteristics and survival outcome in patients with advanced lung adenocarcinoma and KRAS mutation.

Authors:  Shifeng Yang; Xinmin Yu; Yun Fan; Xun Shi; Ying Jin
Journal:  J Cancer       Date:  2018-07-30       Impact factor: 4.207
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.